[go: up one dir, main page]

AU2001261986A1 - Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders - Google Patents

Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Info

Publication number
AU2001261986A1
AU2001261986A1 AU2001261986A AU6198601A AU2001261986A1 AU 2001261986 A1 AU2001261986 A1 AU 2001261986A1 AU 2001261986 A AU2001261986 A AU 2001261986A AU 6198601 A AU6198601 A AU 6198601A AU 2001261986 A1 AU2001261986 A1 AU 2001261986A1
Authority
AU
Australia
Prior art keywords
mediated
cell
treatment
inflammatory disorders
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261986A
Inventor
Anthony E. Bolton
Arkady Mandel
Daniel Sauder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AU2001261986A1 publication Critical patent/AU2001261986A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)

Abstract

Treatment and/or prophylaxis of T-cell-mediated and inflammatory disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, and administration of the apoptotic cells so formed to the patient.
AU2001261986A 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders Abandoned AU2001261986A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,309,518 2000-05-25
CA 2309518 CA2309518A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
PCT/CA2001/000758 WO2001089536A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Publications (1)

Publication Number Publication Date
AU2001261986A1 true AU2001261986A1 (en) 2001-12-03

Family

ID=4166254

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261986A Abandoned AU2001261986A1 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Country Status (11)

Country Link
US (1) US20020051771A1 (en)
EP (2) EP1669081A1 (en)
JP (1) JP2003534281A (en)
AT (1) ATE311191T1 (en)
AU (1) AU2001261986A1 (en)
CA (1) CA2309518A1 (en)
DE (1) DE60115432T2 (en)
DK (1) DK1289534T3 (en)
ES (1) ES2254424T3 (en)
TW (1) TWI249404B (en)
WO (1) WO2001089536A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
DE60235097D1 (en) * 2001-08-13 2010-03-04 Univ Yale METHOD FOR INDUCING A SELECTIVELY IMPRESSED IMMUNE RESPONSE
US20030139466A1 (en) * 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
JP6483023B2 (en) * 2012-12-06 2019-03-13 エンリヴェックス セラピューティクス リミテッド A therapeutic apoptotic cell preparation, its production method and its use
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL303543A (en) * 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
CN113106053A (en) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 Therapeutic pooled apoptotic cell preparation and uses thereof
EP3416661A4 (en) * 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION IMMUNOTHERAPY AND CYTOKIN CONTROL THERAPY FOR TREATING CANCER
WO2023209709A1 (en) * 2022-04-27 2023-11-02 Enlivex Therapeutics Rdo Ltd Apoptotic cell - chemotherapy combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US20030139466A1 (en) * 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis

Also Published As

Publication number Publication date
HK1055079A1 (en) 2003-12-24
CA2309518A1 (en) 2001-11-25
EP1289534B1 (en) 2005-11-30
ES2254424T3 (en) 2006-06-16
JP2003534281A (en) 2003-11-18
EP1289534A2 (en) 2003-03-12
US20020051771A1 (en) 2002-05-02
DE60115432D1 (en) 2006-01-05
ATE311191T1 (en) 2005-12-15
WO2001089536A2 (en) 2001-11-29
TWI249404B (en) 2006-02-21
WO2001089536A3 (en) 2002-08-01
DE60115432T2 (en) 2006-08-24
EP1669081A1 (en) 2006-06-14
DK1289534T3 (en) 2006-03-20

Similar Documents

Publication Publication Date Title
AU2001261986A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
BR9811825A (en) Use of lactobacillus to reduce the level of fibrinogen in the blood
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
CA2129541A1 (en) Method of Promoting Nitrogen Retention in Humans
GEP20063799B (en) Tropane derivatives useful in therapy
DK1071439T3 (en) Hip formulations as anti-inflammatory herbal medicine for the relief / reduction of symptoms associated with inflammation and arthritis
DE3650741D1 (en) Combination of therapeutic nucleosides with other therapeutically active components.
SE9701161D0 (en) New use I
PL330768A1 (en) Perpetration for use in therapy and prophylactics of dermatological diseases
AU2001261987A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
WO2003066071A8 (en) Formulations comprising psychotropic drugs and selenium
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
AU8687391A (en) Lithium treatment
EE200200596A (en) Preparation with a mobilizing effect
WO2001089538A3 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
EP0357646A4 (en) Treatment of aged skin with oral 13-cis-retinoic acid
AU6432899A (en) Use of metformin to counteract weight gain associated with valproate and other psychotropic medications
JP2001316293A5 (en)
PL355292A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
RU94000695A (en) Agent showing antiallergic action
DK0673646T3 (en) Use of deoxyspergualin in the manufacture of a medicament for the treatment of inflammatory-hyper-reactive diseases
CA2115045A1 (en) Composition for Curing Proliferative Skin Diseases
MD2491F1 (en) Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment
MX9102181A (en) IMINOBENZODIAZEPINE FOR THE TREATMENT OF SLEEP DISORDERS